Advanced glycation end product-interventions reduce diabetes-accelerated atherosclerosis

Diabetes

Volumn 53, Issue 7, 2004, Pages 1813-1823

  Forbes, Josephine M ^a   Yee, Louis Teo Loon ^a   Thallas, Vicki ^a   Lassila, Markus ^a   Candido, Riccardo ^a   Jandeleit Dahm, Karin A ^a   Thomas, Merlin C ^a   Burns, Wendy C ^a   Deemer, Elizabeth K ^b   Thorpe, Susan M ^b   Cooper, Mark E ^a   Allen, Terri J ^a  

^a BAKER IDI HEART AND DIABETES INSTITUTE   (Australia)

^b UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4,5 DIMETHYL 3 (2 OXO 2 PHENYLETHYL)THIAZOLIUM; ADVANCED GLYCATION END PRODUCT; ALAGEBRIUM; ALPHA ACTIN; AMINOGUANIDINE; APOLIPOPROTEIN E; CARBOXYETHYLLYSINE; CARBOXYMETHYLLYSINE; COLLAGEN; COLLAGEN TYPE 1; COLLAGEN TYPE 3; COLLAGEN TYPE 4; CONNECTIVE TISSUE GROWTH FACTOR; CYTOKINE; LYSINE DERIVATIVE; THIAZOLE DERIVATIVE; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG;

ABDOMINAL AORTA; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AORTA ARCH; ARTICLE; ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; CONTROLLED STUDY; DIABETES MELLITUS; DISEASE COURSE; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; SOLUBILITY; STREPTOZOCIN DIABETES; THORACIC AORTA; TREATMENT OUTCOME;

ACTINS; ANIMALS; AORTA; ARTERIOSCLEROSIS; COLLAGEN; CYTOKINES; DIABETES MELLITUS, EXPERIMENTAL; DIABETIC ANGIOPATHIES; GLYCOSYLATION END PRODUCTS, ADVANCED; GUANIDINES; LIPID METABOLISM; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MUSCLE, SMOOTH; OXIDATION-REDUCTION; SKIN; THIAZOLES;

EID: 3042704196     PISSN: 00121797     EISSN: None     Source Type: Journal    
DOI: 10.2337/diabetes.53.7.1813     Document Type: Article

References (49)

1. King GL, Wakasaki H: Theoretical mechanisms by which hyperglycemia and insulin resistance could cause cardiovascular diseases in diabetes. Diabetes Care 22 (Suppl 3):C31-C37, 1999
2. Uusitupa MI, Niskanen LK, Siitonen O, Voutilainen E, Pyorala K: 5-Year incidence of atherosclerotic vascular disease in relation to general risk factors, insulin level, and abnormalities in lipoprotein composition in non-insulin-dependent diabetic and nondiabetic subjects. Circulation 82:27-36, 1990
3. Brownlee M, Vlassara H, Kooney A, Ulrich P, Cerami A: Aminoguanidine prevents diabetes-induced arterial wall protein cross-linking. Science 232:1629-1632, 1986
4. Vlassara H, Fuh H, Donnelly T, Cybulsky M: Advanced glycation endproducts promote adhesion molecule (VCAM-1, ICAM-1) expression and atheroma formation in normal rabbits. Mol Med 1:447-456, 1995
5. Menzel EJ, Neumuller J, Sengoelge G, Reihsner R: Effects of aminoguanidine on adhesion molecule expression of human endothelial cells. Pharmacology 55:126-135, 1997.
6. Schmidt AM, Hori O, Chen JX, Li JF, Crandall J, Zhang J, Cao R, Yan SD, Brett J, Stern D: Advanced glycation endproducts interacting with their endothelial receptor induce expression of vascular cell adhesion molecule-1 (VCAM-1) in cultured human endothelial cells and in mice: a potential mechanism for the accelerated vasculopathy of diabetes. J Clin Invest 96:1395-1403, 1995
7. Onorato JM, Jenkins AJ, Thorpe SR, Baynes JW: Pyridoxamine, an inhibitor of advanced glycation reactions, also inhibits advanced lipoxidation reactions: mechanism of action of pyridoxamine. J Biol Chem 275:21177-21184, 2000
8. Degenhardt TP, Alderson NL, Arrington DD, Beattie RJ, Basgen JM, Steffes MW, Thorpe SR, Baynes JW: Pyridoxamine inhibits early renal disease and dyslipidemia in the streptozotocin-diabetic rat. Kidney Int 61:939-950, 2002
9. Alderson NL, Chachich ME, Youssef NN, Beattie RJ, Nachtigal M, Thorpe SR, Baynes JW: The AGE inhibitor pyridoxamine inhibits lipemia and development of renal and vascular disease in Zucker obese rats. Kidney Int 63:2123-2133, 2003
10. Park L, Raman KG, Lee KJ, Lu Y, Ferran LJ Jr, Chow WS, Stern D, Schmidt AM: Suppression of accelerated diabetic atherosclerosis by the soluble receptor for advanced glycation endproducts. Nat Med 4:1025-1031, 1998
11. Schmidt AM, Yan SD, Yan SF, Stern DM: The multiligand receptor RAGE as a progression factor amplifying immune and inflammatory responses. J Clin Invest 108:949-955, 2001
12. Vasan S, Foiles P, Founds H: Therapeutic potential of breakers of advanced glycation end product-protein crosslinks. Arch Biochem Biophys 419:89-96, 2003
13. Forbes JM, Thallas V, Thomas MC, Founds HW, Burns WC, Jerums G, Cooper ME: The breakdown of pre-existing advanced glycation end products is associated with reduced renal fibrosis in experimental diabetes. FASEB J 17:1762-1764, 2003
14. Candido R, Forbes JM, Thomas MC, Thallas V, Dean RG, Burns WC, Tikellis C, Ritchie RH, Twigg SM, Cooper ME, Burrell LM: A breaker of advanced glycation end products attenuates diabetes-induced myocardial structural changes. Circ Res 92:785-792, 2003
15. Kass DA, Shapiro EP, Kawaguchi M, Capriotti AR, Scuteri A, deGroof RC, Lakatta EG: Improved arterial compliance by a novel advanced glycation end-product crosslink breaker. Circulation 104:1464-1470, 2001
16. Candido R, Jandeleit-Dahm KA, Cao Z, Nesteroff SP, Burns WC, Twigg SM, Dilley RJ, Cooper ME, Allen TJ: Prevention of accelerated atherosclerosis by angiotensin-converting enzyme inhibition in diabetic apolipoprotein E-deficient mice. Circulation 106:246-253, 2002
17. Cefalu WT, Wang ZQ, Bell-Farrow A, Kiger FD, Izlar C: Glycohemoglobin measured by automated affinity HPLC correlates with both short-term and long-term antecedent glycemia. Clin Chem 40:1317-1321, 1994
18. Friedewald WT, Levy RI, Fredrickson DS: Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 18:499-502, 1972
19. Krege JH, Hodgin JB, Hagaman JR, Smithies O: A noninvasive computerized tail-cuff system for measuring blood pressure in mice. Hypertension 25:1111-1115, 1995
20. Monnier V, Cerami A: Nonenzymatic browning in vivo: possible process for aging of long-lived proteins. Science 211:491-494, 1981
21. Nakamura K, Nakazawa Y, Ienaga K: Acid-stable fluorescent advanced glycation end products: vesperlysines A, B, and C are formed as crosslinked products in the Maillard reaction between lysine or proteins with glucose. Biochem Biophys Res Commun 232:227-230, 1997
22. Wrobel K, Garay-Sevilla ME, Nava LE, Malacara JM: Novel analytical approach to monitoring advanced glycosylation end products in human serum with on-line spectrophotometric and spectrofluorometric detection in a flow system. Clin Chem 43:1563-1569, 1997
23. Dyer DG, Dunn JA, Thorpe SR, Bailie KE, Lyons TJ, McCance DR, Baynes JW: Accumulation of Maillard reaction products in skin collagen in diabetes and aging. J Clin Invest 91:2463-2469, 1993
24. Stegemann H, Stalder K: Determination of hydroxyproline. Clin Chim Acta 18:267-273, 1967
25. Hsu SM, Raine L, Fanger H: Use of avidin-biotin-peroxidase complex (ABC) in inununoperoxidase techniques: a comparison between ABC and unlabeled antibody (PAP) procedures. JHistochem Cytochem 29:577-580, 1981
26. Twigg SM, Cao Z, McLennan SV, Burns WC, Brammar G, Forbes JM, Cooper ME: Renal connective tissue growth factor induction in experimental diabetes is prevented by aminoguanidine. Endocrinology 143:4907-4915, 2002
27. Makita Z, Vlassara H, Cerami A, Bucala R: Immunochemical detection of advanced glycosylation end products in vivo. J Biol Chem 267:5133-5138, 1992
28. Forbes JM, Hewitson TD, Becker GJ, Jones CL: Ischemic acute renal failure: long-term histology of cell and matrix changes in the rat. Kidney Int 57:2375-2385, 2000
29. Horiuchi S, Sano H, Higashi T, Ikeda K, Jinnouchi Y, Nagai R, Takahashi K: Extra- and intracellular localization of advanced glycation end-products in human atherosclerotic lesions. Nephrol Dial Transplant 11 (Suppl 5):81-86, 1996
30. 1c as markers of diabetic complications: DCCT Skin Collagen Ancillary Study Group: Diabetes Control and Complications Trial. Diabetes 48:870-880, 1999
31. Nathan DM, Lachin J, Cleary P, Orchard T, Brillon DJ, Backlund JY, O'Leary DH, Genuth S: Intensive diabetes therapy and carotid intima-media thickness in type 1 diabetes mellitus. N Engl J Med 348:2294-2303, 2003
32. Degenhardt TP, Thorpe SR, Baynes JW: Chemical modification of proteins by methylglyoxal. Cell Mol Biol (Noisy-le-grand) 44:1139-1145, 1998
33. Miyata T, van Ypersele de Strihou C, Ueda Y, Ichimori K, Inagi R, Onogi H, Ishikawa N, Nangaku M, Kurokawa K: Angiotensin II receptor antagonists and angiotensin-converting enzyme inhibitors lower in vitro the formation of advanced glycation end products: biochemical mechanisms. J Am Soc Nephrol 13:2478-2487, 2002
34. Forbes JM, Cooper ME, Thallas V, Burns WC, Thomas MC, Brammar GC, Lee F, Grant SL, Burrell LA, Jerums G, Osicka TM: Reduction of the accumulation of advanced glycation end products by ACE inhibition in experimental diabetic nephropathy. Diabetes 51:3274-3282, 2002
35. Corbett JA, Tilton RG, Chang K, Hasan KS, Ido Y, Wang JL, Sweetland MA, Lancaster JR Jr, Williamson JR, McDaniel ML: Aminoguanidine, a novel inhibitor of nitric oxide formation, prevents diabetic vascular dysfunction. Diabetes 41:559-556, 1992
36. Kuhlencordt PJ, Chen J, Han F, Astern J, Huang PL: Genetic deficiency of inducible nitric oxide synthase reduces atherosclerosis and lowers plasma lipid peroxides in apolipoprotein E-knockout mice. Circulation 103:3099-3104, 2001
37. Bucciarelli LG, Wendt T, Qu W, Lu Y, Lalla E, Rong LL, Goova MT, Moser B, Kislinger T, Lee DC, Kashyap Y, Stem DM, Schmidt AM: RAGE blockade stabilizes established atherosclerosis in diabetic apolipoprotein E-null mice. Circulation 106:2827-2835, 2002
38. Vasan S, Zhang X, Kapurniotu A, Bernhagen J, Teichberg S, Basgen J, Wagle D, Shih D, Terlecky I, Bucala R, Cerami A, Egan J, Ulrich P: An agent cleaving glucose-derived protein crosslinks in vitro and in vivo. Nature 382:275-278, 1996
39. Wolffenbuttel BH, Boulanger CM, Crijns FR, Huijberts MS, Poitevin P, Swennen GN, Vasan S, Egan JJ, Ulrich P, Cerami A, Levy BI: Breakers of advanced glycation end products restore large artery properties in experimental diabetes. Proc Natl Acad Sci U S A 95:4630-4634, 1998
40. Mentink CJ, Hendriks M, Levels AA, Wolffenbuttel BH: Glucose-mediated cross-linking of collagen in rat tendon and skin. Clin Chim Acta 321:69-76, 2002
41. Yang S, Litchfield JE, Baynes JW: AGE-breakers cleave model compounds, but do not break Maillard crosslinks in skin and tail collagen from diabetic rats. Arch Biochem Biophys 412:42-46, 2003
42. Neumeister V, Scheibe M, Lattke P, Jaross W: Determination of the cholesterol-collagen ratio of arterial atherosclerotic plaques using near infrared spectroscopy as a possible measure of plaque stability. Atherosclerosis 165:251-257, 2002
43. Shiomi M, Ito T, Hirouchi Y, Enomoto M: Fibromuscular cap composition is important for the stability of established atherosclerotic plaques in mature WHHL rabbits treated with statins. Atherosclerosis 157:75-84, 2001
44. Chen J, Kuhlencordt PJ, Astern J, Gyurko R, Huang PL: Hypertension does not account for the accelerated atherosclerosis and development of aneurysms in male apolipoprotein e/endothelial nitric oxide synthase double knockout mice. Circulation 104:2391-2394, 2001
45. Candido R, Allen TJ, Lassila M, Cao Z, Thallas V, Cooper ME, Jandeleit-Dahm K: Irbesartan but not amlodipine suppresses diabetes-associated atherosclerosis. Circulation 109:1536-1542, 2003
46. Iino K, Yoshinari M, Yamamoto M, Kaku K, Doi Y, Ichikawa K, Iwase M, Fujishima M: Effect of glycated collagen on proliferation of human smooth muscle cells in vitro. Diabetologia 39:800-806, 1996
47. Mizutani K, Ikeda K, Yamori Y: Resveratrol inhibits AGEs-induced proliferation and collagen synthesis activity in vascular smooth muscle cells from stroke-prone spontaneously hypertensive rats. Biochem Biophys Res Commun 274:61-67, 2000
48. Hofmann MA, Drury S, Fu C, Qu W, Taguchi A, Lu Y, Avila C, Kambham N, Bierhaus A, Nawroth P, Neurath MF, Slattery T, Beach D, McClary J, Nagashima M, Morser J, Stem D, Schmidt AM: RAGE mediates a novel proinflammatory axis: a central cell surface receptor for S100/calgranulin polypeptides. Cell 97:889-901, 1999
49. Wendt TM, Tanji N, Guo J, Kislinger TR, Qu W, Lu Y, Bucciarelli LG, Rong LL, Moser B, Markowitz GS, Stein G, Bierhaus A, Liliensiek B, Arnold B, Nawroth PP, Stern DM, D'Agati VD, Schmidt AM: RAGE drives the development of glomerulosclerosis and implicates podocyte activation in the pathogenesis of diabetic nephropathy. Am J Pathol 162:1123-1137, 2003